← Browse by Condition
Medical Condition

graves disease

Total Trials
8
Recruiting Now
8
Trial Phases
Phase 2, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for graves disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — graves disease Clinical Trials

How many clinical trials are currently recruiting for graves disease?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for graves disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for graves disease?
graves disease research spans Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a graves disease clinical trial?
Eligibility criteria for graves disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
4
Phase 3
1
Top Sponsors
The First Affiliated Hospital of Xiamen University 1 trial
Elazıg Fethi Sekin Sehir Hastanesi 1 trial
Northwell Health 1 trial
Andrea Goldmann 1 trial
The University of Hong Kong 1 trial

Recruiting Clinical Trials

NCT06068179 Phase 2, Phase 3
Recruiting
Graves' Disease Remission Study: MycoMeth Combo
Enrollment
205 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT07480720
Recruiting
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
Enrollment
100 pts
Location
Turkey (Türkiye)
Sponsor
Elazıg Fethi Sekin Sehir Hasta...
View Trial →
NCT07369063 Phase 2
Recruiting
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
Enrollment
30 pts
Location
United States
Sponsor
Northwell Health
View Trial →
NCT06963203
Recruiting
Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis
Enrollment
486 pts
Location
Belgium, France, Gre...
Sponsor
Andrea Goldmann
View Trial →
NCT06506149
Recruiting
A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease
Enrollment
25 pts
Location
Hong Kong
Sponsor
The University of Hong Kong
View Trial →
NCT07018323 Phase 2
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Enrollment
210 pts
Location
United States, Austr...
Sponsor
Immunovant Sciences GmbH
View Trial →
NCT07017907
Recruiting
Evaluating an AI Tool for Detecting Thyrotoxic States
Enrollment
15 pts
Location
United States
Sponsor
THYROSCOPE INC.
View Trial →
NCT06984627 Phase 2
Recruiting
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
Enrollment
30 pts
Location
Canada, Germany, Ita...
Sponsor
Sanofi
View Trial →

Related Conditions

graves ophthalmopathy (1) hyperthyroidism (1) amiodarone induced thyrotoxicosis (1) thyroidectomy (1) minimally invasive treatment (1) ablation treatment (1) hyperthyroidism thyrotoxicosis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology